Zomedica Corp. (ZOMDF): Nasdaq/NYSE listing notice — Zomedica continues NYSE American listing dialogue after shareholder rejection of reverse split

Zomedica Corp.

Received NYSE American deficiency letter Sept 2023 for 30-day avg share price below $0.20 per Section 1003(f)(v).
Shareholders rejected proposed 80:1 reverse stock split at Feb 28, 2024 special meeting; 67.7% majority required.
Shares remain listed; exchange will monitor price and further deterioration could trigger delisting.
CEO Larry Heaton cites progress and opportunities to positively impact share price.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Zomedica Corp. received a nyse_american deficiency notice notice regarding minimum bid price (rules 1003(f)(v)).

Exchange: nyse american
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 1003(f)(v)

Exact text from the filing

March 13, 2024, Zomedica Corp. (the “Company”) announced that it was continuing its dialogue with the NYSE American LLC (the “NYSE American”) regarding next steps associated with the deficiency letter (the “Letter”) the Company received from NYSE American on September 12, 2023. As reported in a prior Form 8-K, the Letter indicated that the Company was not in compliance with the NYSE American continued listing standards set forth in Section 1003(f)(v) of the NYSE American Company Guide (the “Company Guide”) because the Company’s common shares were trading for a substantial period of time at a l

View on SEC.gov

94 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Zomedica Corp. filing history →

Source: SEC EDGAR

accession 0001654954-24-003187

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.